JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Millward, T. A.
Right arrow Articles by Hemmings, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Millward, T. A.
Right arrow Articles by Hemmings, B. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 48, 33847-33850, November 26, 1999

COMMUNICATION
Ndr Protein Kinase Is Regulated by Phosphorylation on Two Conserved Sequence Motifs*

Thomas A. Millward, Daniel Hess, and Brian A. HemmingsDagger

From the Friedrich Miescher-Institut, Maulbeerstrasse 66, CH-4058 Basel, Switzerland

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Ndr is a nuclear serine/threonine protein kinase that belongs to a subfamily of kinases implicated in the regulation of cell division and cell morphology. This subfamily includes the kinases LATS, Orb6, Cot-1, and Dbf2. We show here that Ndr is potently activated when intact cells are treated with okadaic acid, suggesting that Ndr is normally held in a state of low activity by protein phosphatase 2A. We mapped the regulatory phosphorylation sites of Ndr protein kinase and found that active Ndr is phosphorylated on Ser-281 and Thr-444. Mutation of either site to alanine strongly reduced both basal and okadaic acid-stimulated Ndr activity, while combined mutation abolished Ndr activity completely. Importantly, each of these sites (and also the surrounding sequences) are conserved in the kinase relatives of Ndr, suggesting a general mechanism of activation for kinases of this subfamily. Ser-281 and Thr-444 are also similar to the regulatory phosphorylation sites in several targets of the phosphoinositide-dependent protein kinase PDK1.1 However, PDK1 does not appear to function as an upstream kinase for Ndr. Thus, Ndr and its close relatives may operate in a novel signaling pathway downstream of an as-yet-unidentified kinase with specificity similar to, but distinct from, PDK1.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Human Ndr is a nuclear serine/threonine protein kinase that has been highly conserved during evolution and which is expressed in almost all cell types of the body (1). Sequence comparisons show that, within the protein kinase superfamily, Ndr is most closely related to a subgroup of kinases known to be important in the control of cell growth, cell division, and cell morphology. This subgroup is exemplified by the kinases LATS, Orb6, Cot-1 (50-60% catalytic domain identity with Ndr) and Dbf2 (40% catalytic domain identity with Ndr). Several indications suggest that kinases of this type function, either directly or indirectly, as negative regulators of cyclin/cyclin-dependent kinase complexes. The mammalian LATS kinase (also called Wts) is the product of a tumor suppressor gene and possesses an NH2-terminal domain that is able to directly interact with and inhibit Cdc2 (2, 3). Consistent with this, LATS interacts genetically with Cdc2 in Drosophila. Orb6 overexpression delays the onset of mitosis in fission yeast, and this effect is dependent upon the presence of a functional Wee1 protein, implying that Orb6 can signal through Wee1 to down-regulate Cdc2 activity (4). Dbf2 is part of a network of genes required for down-regulation of Cdc28-cyclin B at the end of mitosis in the budding yeast S. cerevisiae (5). Dbf2 is transiently activated at the metaphase/anaphase transition, coincident with changes in its phosphorylation status, and mutation of Dbf2 causes cells to arrest in late mitosis with high Cdc28 activity (6). Finally, the Cot-1 protein of Neurospora crassa is required for hyphal elongation, although it is not known how Cot-1 functions in this process (7). Ndr thus belongs to a subfamily of kinases that are important in cell growth control. Because of the high degree of homology between the members of this kinase subgroup, it is probable that they share, at least to some extent, related substrates and that they are subject to similar regulation.

In the current work, we have analyzed the regulation of Ndr protein kinase with regard to phosphorylation. Although some members of the kinase family to which Ndr belongs are known to exist as phosphoproteins, their putative regulatory phosphorylation sites have not been mapped. We demonstrate here that the kinase activity of Ndr depends upon phosphorylation of Ndr on two sites, Ser-281 and Thr-444. Both of these sites, as well as the sequences surrounding them, are highly conserved in LATS, Orb6, and Cot-1 and are also present (albeit with slightly lower homology) in Dbf2. Ser-281 and Thr-444 of Ndr are also similar to phosphorylation sites in several PDK1 substrates, but despite this Ndr does not appear to be a target of PDK1. Thus, Ndr and its kinase relatives may be regulated by an upstream kinase distinct from PDK1, but with PDK1-like specificity.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture-- COS-1 and 293 cells were transfected as described previously (8, 9). Cells were treated for 1 h with 1 µM okadaic acid (Alexis Corp.) or with solvent alone (0.8% N,N-dimethylformamide) in serum-containing medium. Alternatively, cells were starved in Dulbecco's modified Eagle's medium lacking serum for 24 h and then stimulated with 100 nM insulin or 50 ng/ml IGF-1 (Roche Molecular Biochemicals) for 10 min. The following plasmids were used for transfection: pECE.HA-Ndr-WT (10), pcDNA3.HA-Ndr-WT, and various derivative plasmids encoding phosphorylation site mutants (see below), pCMV5.myc-PDK1 (11) and pECE.HA-Delta PH-PKB (12). Immune complex kinase assays for HA-Ndr and for endogenous Ndr were carried out as described (10). HA-Delta PH-PKB was immunoprecipitated and assayed for kinase activity in the same way as HA-Ndr, except that 50 µg (0.1 mg/ml) cell extract was used, and the kinase substrate used was Crosstide (GRPRTSSFAEG; 30 µM). Immunoblotting was carried out as described (10), using monoclonal antibodies 12CA5 or 9E10 or a polyclonal antibody against phosphorylated Ser-473 of PKB (New England Biolabs).

Purification of HA-Ndr-- Extracts from transfected COS-1 cells (10-15 mg of protein) were mixed with ~200 µg of 12CA5 prebound to 100 µl of protein A-Sepharose beads. After washing, bound proteins were eluted with 1 ml of buffer containing 50 mM Tris-HCl, pH 7.5, 0.1% NP-40, 4 µM leupeptin, 1 mM benzamidine, 1 µM microcystin, and 1 mg/ml HA peptide (YPYDVPDYA) and then precipitated by the addition of 125 µg/ml sodium deoxycholate and 10% trichloroacetic acid (13). Precipitated proteins were run on a 7.5% preparative SDS-polyacrylamide gel which was then stained with Coomassie Blue. Bands corresponding to HA-Ndr were excised.

Mass Spectrometry-- HA-Ndr in gel slices was reduced with dithiothreitol, alkylated with iodoacetamide, and digested with trypsin (14). NanoESI mass spectrometry (ESI-MS-MS) was performed according to Wilm and Mann (15), and phosphopeptides were detected by m/z -79 precursor ion scanning (16). The mass spectra were acquired on an API 300 triple quadrupole mass spectrometer (PE Sciex, Toronto, Ontario, Canada) equipped with a NanoESI source (Protana, Odense, Denmark). To estimate phosphorylation stoichiometry, peptides were fractionated by LC-MS (17). Phospho- and dephosphopeptides were detected by extraction of the MS data for the corresponding ions.

Metabolic Cell Labeling-- COS-1 cells in 10-cm dishes were transfected with pECE.HA-Ndr-WT. After 72 h the medium was changed to phosphate-free Dulbecco's modified Eagle's medium containing 10% dialyzed fetal calf serum and 1 mCi/plate of 32Pi (Amersham Pharmacia Biotech). After a further 5 h the cells were stimulated with okadaic acid, harvested, and HA-Ndr purified as described above.

Phosphoamino Acid Analysis and Phosphate Release-- Tryptic phosphopeptides were separated by LC-MS and the 32P-phosphopeptides P1 and P4 identified by their molecular masses (17). An aliquot (200 cpm) of each purified 32P-phosphopeptide was lyophilized and then hydrolyzed in 6M HCl containing 0.2 mg/ml bovine serum albumin at 110 °C for 45 min. The hydrolysate was separated by thin layer electrophoresis at pH 3.5 (18) and radioactivity detected using a PhosphorImager (Molecular Dynamics). In parallel, 400 cpm of each 32P-phosphopeptide was subjected to solid-phase Edman degradation using an automated model 477A sequenator (Applied Biosystems). Fractions from each cycle of Edman degradation were lyophilized, redissolved in 50% acetonitrile, and spotted onto a thin layer chromatography plate, before exposure to a PhosphorImager screen.

Site-directed Mutagenesis-- The insert of the plasmid pECE.HA-Ndr-WT was cloned between the KpnI and XbaI sites of pcDNA3 (Invitrogen) to generate pcDNA3.HA-Ndr-WT. Ser-281 and Thr-444 were mutagenized using QuickChange (Stratagene).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mapping of Regulatory Phosphorylation Sites in Ndr-- We observed that the activity of both transfected and endogenous Ndr was potently stimulated upon treatment of intact cells with okadaic acid (OA) at concentrations that would result in specific inhibition of protein phosphatase 2A (19). Moreover, in vitro incubation of Ndr with purified protein phosphatase 2A resulted in a complete loss of Ndr activity (data not shown). These findings prompted us to map the regulatory phosphorylation sites in Ndr that are essential for its activity. COS-1 cells expressing HA-Ndr were treated with OA or with solvent alone, and HA-Ndr was then immunopurified using the 12CA5 monoclonal antibody. Approximately 1 µg of purified HA-Ndr was digested with trypsin, and the resultant mixture of peptides was analyzed by ESI-MS-MS in a -79 precursor scan (16). This procedure measures the mass:charge ratio (m/z) of each peptide in the mixture that, upon fragmentation, liberates a species with a m/z of -79 (corresponding to a single phosphate group).

When HA-Ndr from control cells was analyzed in this way, only weak phosphopeptide signals could be detected (Fig. 1A). In HA-Ndr from OA-treated cells, however, the abundance of phosphopeptides was markedly increased (Fig. 1B). The observed m/z of each of these peaks could be accounted for by five Ndr-derived peptides, each of which was ~79 Da heavier than would be expected for the nonphosphorylated state (Fig. 1C). The identities of several of these phosphopeptides were also confirmed by partial sequencing (data not shown). The five phosphopeptides derive from two regions of the Ndr polypeptide. The first group of phosphopeptides (P1, P2, and P3) are from a region of the Ndr kinase domain that corresponds to the activation-loop (or T-loop) of other kinases (Ndr amino acids 277-301). The second group of phosphopeptides (P4 and P5) come from the carboxyl-terminal region of the Ndr polypeptide ~60 amino acids COOH-terminal to the catalytic domain (Ndr amino acids 437-447). Each of these regions contains three amino acids that could potentially be phosphorylated (marked in bold in Fig. 1C). To precisely locate each phosphorylation site, HA-Ndr was isolated from cells that had been metabolically labeled with 32Pi prior to OA treatment, and tryptic peptides were purified chromatographically; one phosphopeptide from each region (P1 from Ndr amino acids 277-294, and P4 from Ndr amino acids 437-446) was then selected for further analysis. As shown in Fig. 1D, phosphopeptide P1 gave rise exclusively to phosphoserine upon acid hydrolysis, and released radioactivity in the fifth cycle of Edman degradation, demonstrating phosphorylation of Ser-281. In contrast, phosphopeptide P4 contained phosphothreonine, and released 32P in cycle 8 of Edman degradation, showing that Thr-444 is phosphorylated (Fig. 1E). These results demonstrate that cell stimulation with OA results in the phosphorylation of two sites in Ndr and that these two sites are Ser-281 and Thr-444.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 1.   Mapping of regulatory phosphorylation sites in Ndr protein kinase. A and B, ESI-MS-MS -79 precursor scan for phosphopeptides in HA-Ndr immunopurified from control (A) or OA-treated (B) COS-1 cells. Phosphopeptides whose m/z could be assigned to Ndr-derived peptides are labeled P1 through P5. Most of these peptides were detected in several different charged states, designated [M - 2H]2-, [M - 3H]3-, and so on. A methionine residue in peptides P1 and P2 was found to be oxidized; this oxidation presumably occurred during purification. P2 and P3 result from trace chymotryptic contamination of the trypsin preparation, since they both terminate with aromatic residues at the carboxyl-terminal end. C, the phosphopeptides from Fig. 1B, which derive from two regions of the Ndr polypeptide, are summarized with potential phosphoacceptors in each peptide marked in bold. D and E, phosphoamino acid analysis (upper panels) and phosphate release (lower panels) of 32P-phosphopeptides P1 (D) and P4 (E) purified from metabolically labeled, OA-treated COS-1 cells expressing HA-Ndr. Positions of ninhydrin-stained phosphoamino acid standards are shown above the upper panels. 32P release by Edman degradation was detected by spotting sequenator fractions onto thin layer chromatography plates, followed by exposure to a PhosphorImager.

Phosphorylation Stoichiometry of Ser-281 and Thr-444-- A portion of the tryptic peptides from Fig. 1, A and B, were analyzed by LC-MS to estimate the relative abundance of phosphorylated and dephosphorylated forms of Ser-281- and Thr-444-containing peptides. Assuming equal elution efficiency of phospho- and dephospho-forms, both Ser-281 and Thr-444 in Ndr from control cells were phosphorylated to a stoichiometry of ~0.1 mol/mol, consistent with the fact that HA-Ndr from unstimulated cells has a low but measurable level of basal activity (see Fig. 2). Upon OA treatment, Ser-281 phosphorylation rose to ~0.8 mol/mol, while Thr-444 phosphorylation rose to ~0.5 mol/mol (data not shown).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 2.   Phosphorylation of Ser-281 and Thr-444 is required for Ndr activity. COS-1 cells expressing either wild-type HA-Ndr or the indicated mutants were treated for 1 h with solvent alone (open bars) or with 1 µM OA (filled bars). HA-tagged kinases were then immunoprecipitated and assayed for kinase activity (upper panel). Data are the mean ± S.D. of duplicate immunoprecipitations. In the lower panel, protein extracts (10 µg) were analyzed by immunoblotting with 12CA5 to verify similar expression levels of each Ndr construct.

Ndr Requires Phosphorylation on Ser-281 and Thr-444 for Its Activity-- Ndr mutants were created in which either Ser-281 or Thr-444 was replaced by alanine. The protein kinase activity of each of these mutants was measured following cell treatment with OA or with solvent alone. HA-Ndr-WT was potently (~25-fold) stimulated by OA (Fig. 2). Both the S281A and T444A mutants had markedly reduced basal kinase activity but were still activated (15-20-fold) by OA. However, combined mutation of the two sites (S281A/T444A) reduced basal activity to near undetectable levels and abolished the ability of Ndr to be stimulated by OA. Western blot analysis confirmed that the various mutants were expressed at comparable levels (Fig. 2). These results confirm that Ndr requires phosphorylation on Ser-281 and Thr-444 for its activity.

We also attempted to create constitutively active mutants of Ndr by replacing Ser-281 and/or Thr-444 with negatively charged amino acids. S281D and S281E mutants had basal and OA-stimulated activities similar to those of the S281A mutant, suggesting that steric constraints in this region of the molecule are too tight to allow effective mimicry of a phosphate group by a negatively charged amino acid side chain (data not shown). T444D and T444E mutants had moderately (1.5-2-fold) elevated basal kinase activity (data not shown).

Ser-281 and Thr-444 Are Conserved in Ndr-related Kinases-- Comparison of the sequence of Ndr with those of the closely related kinases LATS, Orb6, and Cot-1 shows that potential phosphorylation sites corresponding to both Ser-281 and Thr-444 are conserved throughout the family (Fig. 3). Moreover, the sequences surrounding these sites are highly conserved. It is therefore probable that Orb6, LATS and Cot-1 are also regulated by phosphorylation on sites equivalent to Ser-281 and Thr-444 of Ndr. Dbf2 also contains potential phosphorylation sites at positions equivalent to Ser-281 and Thr-444 of Ndr; however the sequences surrounding these sites are somewhat less well conserved (not shown).


View larger version (61K):
[in this window]
[in a new window]
 
Fig. 3.   Potential phosphorylation sites homologous to Ser-281 and Thr-444 of Ndr are present in several Ndr-related kinases. In the upper panel, the catalytic domain homologies (amino acid identity) between Ndr and the kinases LATS, Orb6, and Cot-1 are shown. In the lower panel, the sequences surrounding Ser-281 and Thr-444 of Ndr are aligned with the corresponding regions of LATS, Orb6, and Cot-1. Identical amino acids are shown in white on a black background, and conservative substitutions are shown in black on a gray background. Roman numerals denote protein kinase catalytic subdomains (28).

Evidence That Ndr Is Not a Target of PDK1-- Ser-281 of Ndr shows significant homology to a site in several protein kinases that are substrates for the phosphoinositide-dependent kinase PDK1 (see "Discussion"). We therefore tested the possibility that Ndr too might be a target of PDK1. Myc-tagged PDK1 was coexpressed with HA-Ndr in HEK-293 cells, and Ndr was then immunoprecipitated and assayed for kinase activity. PDK1 overexpression had very little effect on HA-Ndr activity (Fig. 4A), although it was readily detectable by Western blotting (Fig. 4B). In the same experiment, PDK1 caused a >20-fold activation of Delta PH-PKB, an established PDK1 substrate (12). Immunoprecipitated myc-PDK1 also failed to transfer phosphate to a complex of GST-Ndr K118A with Ca2+/S100B in vitro (10), although it autophosphorylated efficiently (data not shown).


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 4.   Evidence that Ndr is not a target of PDK1. A, 293 cells were transfected with plasmids encoding HA-Ndr (5 µg DNA) or HA-Delta PH-PKB (5 µg DNA), together with 0, 1, or 5 µg of plasmid encoding myc-PDK1 as indicated below the graph. After transfection, cells were serum-starved for 24 h and then HA-tagged kinases were immunoprecipitated and assayed for kinase activity. Bars represent mean ± S.D. of duplicate immunoprecipitations. B, protein extracts (10 µg) from Fig. 4A were immunoblotted with 12CA5 (upper panel) to verify expression of HA-Ndr and HA-Delta PH-PKB or with 9E10 (lower panel) to verify expression of myc-PDK1. C, 293 cells were serum-starved and were then left untreated or were treated with insulin or IGF-1 (left panel). Alternatively, asynchronously growing 293 cells were treated with solvent alone or with OA (right panel). Endogenous Ndr activity was then determined in each cell extract by immune complex kinase assay; bars represent mean ± S.D. of duplicate immunoprecipitations. D, the cell extracts used in Fig. 4C (30 µg/lane) were immunoblotted with an antibody that recognizes the activated form of PKB, phosphorylated on Ser-473.

Several PDK1 substrates are activated when cells are exposed to insulin or IGF-1. We investigated whether these ligands are able to activate endogenous Ndr in HEK-293 cells. We found that endogenous Ndr was activated ~15-fold by OA, but showed no response to either insulin or IGF-1 (Fig. 4C). The same extracts used to measure Ndr kinase activity in Fig. 4C were immunoblotted using a phosphospecific antibody that recognizes phosphorylated Ser-473 of PKB (which is similar to Thr-444 of Ndr). As expected, phosphorylation of PKB Ser-473 was strongly induced by both insulin and IGF-1 (Fig. 4D). The lack of activation of Ndr by insulin or IGF-1 was confirmed using epitope-tagged Ndr overexpressed in HEK-293 cells (data not shown). Since Ndr was not activated under conditions that promote phosphorylation and activation of PKB, it would appear that the kinase that activates Ndr is distinct from the kinase responsible for phosphorylation of PKB.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this paper, we have shown that the activity of Ndr protein kinase is critically dependent on phosphorylation at two sites, Ser-281 and Thr-444. Based on these results, we predict that LATS, Orb6, Cot-1, and possibly Dbf2 are regulated by phosphorylation on homologous sites. Both Ser-281 and Thr-444 must be phosphorylated for full Ndr activity, but phosphorylation of either site alone is sufficient for a more limited degree of activity. Two of the kinases closely related to Ndr, LATS and Dbf2, are already known to exist as phosphoproteins, although their phosphorylation sites have not been mapped (3, 6). Both LATS and Dbf2 are phosphorylated in a cell cycle-dependent manner, as shown by cell cycle stage-dependent changes in their mobility on SDS gels that can be reversed by in vitro treatment with calf intestinal phosphatase. Ndr protein kinase is the closest known relative of the tumor suppressor LATS in mammalian cells, and several tissues and cell types co-express Ndr and LATS. The high level of homology of these kinases in regions targeted for phosphorylation in Ndr suggests the possibility that they could be regulated by the same upstream kinase.

Ser-281 of Ndr shows homology to activation-loop phosphorylation sites that are found in several members of the AGC subgroup of serine/threonine kinases, such as PKB/Akt (20), p70 S6 kinase (11, 21), SGK (22, 23), protein kinase C (24, 25), and cAMP-dependent protein kinase (26). The activation-loop site in each of these kinases is a substrate for PDK1. Based on sequence comparisons, Cheng et al. (26) proposed a consensus phosphorylation motif for PDK1 as Thr-Xaa-Cys-Gly-Thr-Xaa-Asp/Glu-Tyr-Xaa-Ala-Pro-Glu, where Xaa is a hydrophobic residue, and the first Thr in the sequence is the phosphoacceptor. The sequence around Ser-281 of Ndr is homologous to this consensus in 9 out of 12 positions. Moreover, most PDK1 targets contain a second phosphorylation site approximately 60 amino acids carboxyl-terminal to the end of the kinase catalytic domain, which is flanked by hydrophobic amino acids (consensus Phe-Xaa-Xaa-Phe-Ser/Thr-Phe/Tyr) and which, at least in the case of PKB, is phosphorylated by a modified form of PDK1 (27). Thr-444 of Ndr shows similarity to this second motif both in terms of the sequence surrounding it and in terms of its positioning within the polypeptide chain. However, our results suggest that Ndr is not phosphorylated by PDK1. One potential explanation for this could be an unusual structural feature present in Ndr. As shown in Fig. 3, Ndr and its close relatives contain an insert of ~40 amino acids between the catalytic subdomains VII and VIII, which is absent from all other known kinases. This insert interrupts the canonical kinase catalytic domain, beginning COOH-terminally to the conserved "DFG" kinase motif and ending directly NH2-terminal to Ser-281. The close proximity of this domain to Ser-281 might influence the recognition of Ser-281 by upstream kinases, such that phosphorylation by PDK1 is prevented. Moreover, in Ndr this domain harbors a nuclear localization signal so that in the cell, Ndr and PDK1 may be separated from each other in distinct compartments (1). Taken together, our results suggest that Ndr might be the target of an as-yet-unidentified nuclear activation loop kinase that has a substrate specificity similar to, but distinct from, PDK1. In addition, the stimulation of Ndr activity by OA in intact cells, as well as the ability of protein phosphatase 2A to inactivate Ndr in vitro, indicate that Ndr may be a physiological substrate of protein phosphatase 2A.

    ACKNOWLEDGEMENTS

We thank Renate Matthies for phosphopeptide purification and phosphate release, Iwan Beuwink for help and advice in metabolic cell labeling and detection of radioactivity in Sequenator fractions, Dr. Nick Pullen for help with phosphoamino acid analysis, and Jongsun Park for PDK1 and PKB expression plasmids. We thank Dr. Tom Sturgill and Dr. Sauveur-Michel Maira for critical reading of the manuscript.

    FOOTNOTES

* This work was supported by Krebsforschung Schweiz Grant KFS 269-1-1996 (to B. A. H.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 41-61-697-40-46; Fax: 41-61-697-39-76; E-mail: hemmings@fmi.ch.

    ABBREVIATIONS

The abbreviations used are: PDK1, phosphoinositide-dependent kinase-1; HA, hemagglutinin; OA, okadaic acid; ESI-MS-MS, electrospray ionization mass spectrometry; LC-MS, liquid chromatography interfaced with electrospray mass spectrometry; WT, wild-type.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Millward, T., Cron, P., and Hemmings, B. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5022-5026[Abstract/Free Full Text]
2. St. John, M. A., Tao, W., Fei, X., Fukumoto, R., Carcangiu, M. L., Brownstein, D. G., Parlow, A. F., McGrath, J., and Xu, T. (1999) Nat. Genet. 21, 182-186[CrossRef][Medline] [Order article via Infotrieve]
3. Tao, W., Zhang, S., Turenchalk, G. S., Stewart, R. A., St John, M. A., Chen, W., and Xu, T. (1999) Nat. Genet. 21, 177-181[CrossRef][Medline] [Order article via Infotrieve]
4. Verde, F., Wiley, D. J., and Nurse, P. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7526-7531[Abstract/Free Full Text]
5. Jaspersen, S. L., Charles, J. F., Tinker-Kulberg, R. L., and Morgan, D. O. (1998) Mol. Biol. Cell 9, 2803-2817[Abstract/Free Full Text]
6. Toyn, J. H., and Johnston, L. H. (1994) EMBO J. 13, 1103-1113[Medline] [Order article via Infotrieve]
7. Yarden, O., Plamann, M., Ebbole, D. J., and Yanofsky, C. (1992) EMBO J. 11, 2159-2166[Medline] [Order article via Infotrieve]
8. Seed, B., and Aruffo, A. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 3365-3369[Abstract/Free Full Text]
9. Chen, C., and Okayama, H. (1987) Mol. Cell. Biol. 7, 2745-2752[Abstract/Free Full Text]
10. Millward, T. A., Heizmann, C. W., Schafer, B. W., and Hemmings, B. A. (1998) EMBO J. 17, 5913-5922[CrossRef][Medline] [Order article via Infotrieve]
11. Pullen, N., Dennis, P. B., Andjelkovic, M., Dufner, A., Kozma, S. C., Hemmings, B. A., and Thomas, G. (1998) Science 279, 707-710[Abstract/Free Full Text]
12. Andjelkovic, M., Maira, S. M., Cron, P., Parker, P. J., and Hemmings, B. A. (1999) Mol. Cell. Biol. 19, 5061-5072[Abstract/Free Full Text]
13. Bensadoun, A., and Weinstein, D. (1976) Anal. Biochem. 70, 241-250[CrossRef][Medline] [Order article via Infotrieve]
14. Shevchenko, A., Wilm, M., Vorm, O., and Mann, M. (1996) Anal. Chem. 68, 850-858[Medline] [Order article via Infotrieve]
15. Wilm, M., and Mann, M. (1996) Anal. Chem. 68, 1-8[Medline] [Order article via Infotrieve]
16. Carr, S. A., Huddelstone, M. J., and Annan, R. S. (1996) Anal. Biochem. 239, 180-192[CrossRef][Medline] [Order article via Infotrieve]
17. Krieg, J., Hartmann, S., Vicentini, A., Gläsner, W., Hess, D., and Hofsteenge, J. (1998) Mol. Biol. Cell 9, 301-309[Abstract/Free Full Text]
18. Duclos, B., Marcandier, S., and Cozzone, A. J. (1991) Methods Enzymol. 201, 10-21[Medline] [Order article via Infotrieve]
19. Favre, B., Turowski, P., and Hemmings, B. A. (1997) J. Biol. Chem. 272, 13856-13863[Abstract/Free Full Text]
20. Alessi, D. R., Deak, M., Casamayor, A., Caudwell, F. B., Morrice, N., Norman, D. G., Gaffney, P., Reese, C. B., MacDougall, C. N., Harbison, D., Ashworth, A., and Bownes, M. (1997) Curr. Biol. 7, 776-789[CrossRef][Medline] [Order article via Infotrieve]
21. Alessi, D. R., Kozlowski, M. T., Weng, Q. P., Morrice, N., and Avruch, J. (1998) Curr. Biol. 8, 69-81[CrossRef][Medline] [Order article via Infotrieve]
22. Kobayashi, T., and Cohen, P. (1999) Biochem. J. 339, 319-328
23. Park, J., Leong, M. L., Buse, P., Maiyar, A. C., Firestone, G. L., and Hemmings, B. A. (1999) EMBO J. 18, 3024-3033[CrossRef][Medline] [Order article via Infotrieve]
24. Dutil, E. M., Toker, A., and Newton, A. C. (1998) Curr. Biol. 8, 1366-1375[CrossRef][Medline] [Order article via Infotrieve]
25. Le Good, J. A., Ziegler, W. H., Parekh, D. B., Alessi, D. R., Cohen, P., and Parker, P. J. (1998) Science 281, 2042-2045[Abstract/Free Full Text]
26. Cheng, X., Ma, Y., Moore, M., Hemmings, B. A., and Taylor, S. S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 9849-9854[Abstract/Free Full Text]
27. Balendran, A., Casamayor, A., Deak, M., Paterson, A., Gaffney, P., Currie, R., Downes, C. P., and Alessi, D. R. (1999) Curr. Biol. 9, 393-404[CrossRef][Medline] [Order article via Infotrieve]
28. Hanks, S. K., and Hunter, T. (1995) FASEB J. 9, 576-596[Abstract]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Cell Biol.Home page
J. M. Jansen, M. F. Barry, C. K. Yoo, and E. L. Weiss
Phosphoregulation of Cbk1 is critical for RAM network control of transcription and morphogenesis
J. Cell Biol., December 4, 2006; 175(5): 755 - 766.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Suzuki, T. Ogura, and H. Esumi
NDR2 Acts as the Upstream Kinase of ARK5 during Insulin-like Growth Factor-1 Signaling
J. Biol. Chem., May 19, 2006; 281(20): 13915 - 13921.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. R. Stegert, A. Hergovich, R. Tamaskovic, S. J. Bichsel, and B. A. Hemmings
Regulation of NDR Protein Kinase by Hydrophobic Motif Phosphorylation Mediated by the Mammalian Ste20-Like Kinase MST3
Mol. Cell. Biol., December 15, 2005; 25(24): 11019 - 11029.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. Hergovich, S. J. Bichsel, and B. A. Hemmings
Human NDR Kinases Are Rapidly Activated by MOB Proteins through Recruitment to the Plasma Membrane and Phosphorylation
Mol. Cell. Biol., September 15, 2005; 25(18): 8259 - 8272.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
Y. He, K. Emoto, X. Fang, N. Ren, X. Tian, Y.-N. Jan, and P. N. Adler
Drosophila Mob Family Proteins Interact with the Related Tricornered (Trc) and Warts (Wts) Kinases
Mol. Biol. Cell, September 1, 2005; 16(9): 4139 - 4152.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
Y. He, X. Fang, K. Emoto, Y.-N. Jan, and P. N. Adler
The Tricornered Ser/Thr Protein Kinase Is Regulated by Phosphorylation and Interacts with Furry during Drosophila Wing Hair Development
Mol. Biol. Cell, February 1, 2005; 16(2): 689 - 700.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. J. Bichsel, R. Tamaskovic, M. R. Stegert, and B. A. Hemmings
Mechanism of Activation of NDR (Nuclear Dbf2-related) Protein Kinase by the hMOB1 Protein
J. Biol. Chem., August 20, 2004; 279(34): 35228 - 35235.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
T. J. Kottom and A. H. Limper
Pneumocystis carinii Cell Wall Biosynthesis Kinase Gene CBK1 Is an Environmentally Responsive Gene That Complements Cell Wall Defects of cbk-Deficient Yeast
Infect. Immun., August 1, 2004; 72(8): 4628 - 4636.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Devroe, H. Erdjument-Bromage, P. Tempst, and P. A. Silver
Human Mob Proteins Regulate the NDR1 and NDR2 Serine-Threonine Kinases
J. Biol. Chem., June 4, 2004; 279(23): 24444 - 24451.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. R. Stegert, R. Tamaskovic, S. J. Bichsel, A. Hergovich, and B. A. Hemmings
Regulation of NDR2 Protein Kinase by Multi-site Phosphorylation and the S100B Calcium-binding Protein
J. Biol. Chem., May 28, 2004; 279(22): 23806 - 23812.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M.-C. Hou, D. A. Guertin, and D. McCollum
Initiation of Cytokinesis Is Controlled through Multiple Modes of Regulation of the Sid2p-Mob1p Kinase Complex
Mol. Cell. Biol., April 15, 2004; 24(8): 3262 - 3276.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
D. G. Wansink, R. E. M. A. van Herpen, M. M. Coerwinkel-Driessen, P. J. T. A. Groenen, B. A. Hemmings, and B. Wieringa
Alternative Splicing Controls Myotonic Dystrophy Protein Kinase Structure, Enzymatic Activity, and Subcellular Localization
Mol. Cell. Biol., August 15, 2003; 23(16): 5489 - 5501.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Kamikubo, A. Takaori-Kondo, T. Uchiyama, and T. Hori
Inhibition of Cell Growth by Conditional Expression of kpm, a Human Homologue of Drosophila warts/lats Tumor Suppressor
J. Biol. Chem., May 9, 2003; 278(20): 17609 - 17614.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Tamaskovic, S. J. Bichsel, H. Rogniaux, M. R. Stegert, and B. A. Hemmings
Mechanism of Ca2+-mediated Regulation of NDR Protein Kinase through Autophosphorylation and Phosphorylation by an Upstream Kinase
J. Biol. Chem., February 21, 2003; 278(9): 6710 - 6718.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Adeyinka, E. Emberley, Y. Niu, L. Snell, L. C. Murphy, H. Sowter, C. C. Wykoff, A. L. Harris, and P. H. Watson
Analysis of Gene Expression in Ductal Carcinoma in Situ of the Breast
Clin. Cancer Res., December 1, 2002; 8(12): 3788 - 3795.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. S. Mah, J. Jang, and R. J. Deshaies
Protein kinase Cdc15 activates the Dbf2-Mob1 kinase complex
PNAS, June 7, 2001; (2001) 141098998.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
I. Tan, K. T. Seow, L. Lim, and T. Leung
Intermolecular and Intramolecular Interactions Regulate Catalytic Activity of Myotonic Dystrophy Kinase-Related Cdc42-Binding Kinase {alpha}
Mol. Cell. Biol., April 15, 2001; 21(8): 2767 - 2778.
[Abstract] [Full Text]


Home page
Mol. Cell. Biol.Home page
S. Bidlingmaier, E. L. Weiss, C. Seidel, D. G. Drubin, and M. Snyder
The Cbk1p Pathway Is Important for Polarized Cell Growth and Cell Separation in Saccharomyces cerevisiae
Mol. Cell. Biol., April 1, 2001; 21(7): 2449 - 2462.
[Abstract] [Full Text]


Home page
GeneticsHome page
W. Geng, B. He, M. Wang, and P. N. Adler
The tricornered Gene, Which Is Required for the Integrity of Epidermal Cell Extensions, Encodes the Drosophila Nuclear DBF2-Related Kinase
Genetics, December 1, 2000; 156(4): 1817 - 1828.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. S. Mah, J. Jang, and R. J. Deshaies
Protein kinase Cdc15 activates the Dbf2-Mob1 kinase complex
PNAS, June 19, 2001; 98(13): 7325 - 7330.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Millward, T. A.
Right arrow Articles by Hemmings, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Millward, T. A.
Right arrow Articles by Hemmings, B. A.